-------------------------------------------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------------------------------------------

Description:
Megavac-R vaccine contains tissue culture Rabies virus, CVS strain, produced on BHK21 cell line, and inactivated with aziridine compound. Aluminium hydroxide gel is used as adjuvant. Each ml of Megavac-R contains antigen potency > 2.0 I.U. Megavac-R is recommended for immunisation of dogs and other domestic animals against rabies for prophylactic vaccination. 

--------------------------------------------------------------------------------------------------------------------------

Administration:
The vaccine vial should be thoroughly shaken before the contents are withdrawn. Only sterile syringes and needles should be used. The vaccine should be injected subcutaneously or intramuscularly through an area of clean, dry skin with all precautions taken against contamination.

--------------------------------------------------------------------------------------------------------------------------

Dosage:
1ml by subcutaneous or intramuscular route.

--------------------------------------------------------------------------------------------------------------------------

Vaccination Regimen:
Prophylactic use : At 3 months of age and above. In case primary vaccination is given below 3 months, a booster dose should be given at 3 months age. ·

--------------------------------------------------------------------------------------------------------------------------

Immunity:
Immunity is conferred for a period of 2 years. However, annual vaccination is recommended in endemic areas.

--------------------------------------------------------------------------------------------------------------------------

Presentation:
Single dose (1ml) with a vaccination tag as per recommendation of CDC and a disposable syringe.

Multi dose vial of 10ml.
--------------------------------------------------------------------------------------------------------------------------